Torvacard (20 mg) Atorvastatin

ʻO ka palapala dosage no ka hoʻokuʻu ʻana iā Torvacard i nā pā kihi ʻoniʻoni: convex, oval, kokoke i keʻokeʻo a ʻū paha keʻokeʻo ma nā ʻaoʻao ʻelua (10 mau pcs i kahi blister, 3 a 9 paha i loko o kahi pā o ka pepa).

ʻO ka papa kai ola: atorvastatin (ma ke ʻano o ka calcium), ma 1 papa - 10, 20 a 40 mg paha.

ʻO nā mea kōkua: nā hana hyprolose haʻahaʻa, lactose monohidate, magnesium stearate, sodium croscarmellose, magnesium oxide, colloidal silicon dioxide, microcrystalline cellulose.

Hōʻike Shell: macrogol 6000, hypromellose 2910/5, talc, titanium dioxide.

Pākuʻi helu

Nā Papa Hoʻohala 10 mg, 20 mg, 40 mg

Aia ma ka papa papa

mea waiwai - atorvastatin 10.00 mg, 20.00 mg, 40.00 mg (as

atorvastatin calcium 10.34 mg, 20.68 mg, 41.36 mg, kekona)

nā mea hoʻohālikelike: magnesium oxide (kaumaha), microcrystalline cellulose, lactose monohidate (26.30 mg - no nā papa me kahi maʻi o 10 mg, 52.60 mg - no nā papa me kahi maʻi o 20 mg, 105.20 mg - no nā papa me kahi maʻi he 40 mg), ka sela croscarmellose, haʻahaʻa haʻahaʻa hydroxypropyl cellulose LH 21, anhydrous colloidal silicon, magnesium stearate

ukana moku: hypromellose 2910/5, macrogol 6000, titanium dioxide E171, talc

Nā pālani, i hui ʻia me ka ʻula o ke keʻokeʻo a i ʻole keʻokeʻo paha ke aniani, oval, me kahi biconvex, ma kahi o 9.0 x 4.5 mm ka nui (no nā keneta o 10 mg).

Nā pālani, i hui ʻia me ka ʻula o ke keʻokeʻo a i ʻole keʻokeʻo paha ke ʻaukā, i ʻōhali ʻia me ke ʻano, me ka maka o ka biconvex, he 12,0 x 6.0 mm ka nui (no nā keneta o 20 mg).

Nā pālani, i hui pū ʻia me ka ʻula o ke keʻokeʻo a i ʻole keʻokeʻo paha ke aniani, oval, me kahi biconvex, he 13m x 6.9 mm ka nui (no nā dosis 40 mg).

ʻO nā waiwai Pharmacological

Lapaʻau lāʻau

Paʻi koke ʻo Atorvastatin ma hope o ka hoʻokele waha, ke loaʻa ʻana o ka wela plasma (Cmax) nui i loko o 1-2 mau hola. ʻO ka pae o ke kīhū a me ka ʻike o ka atorvastatin i ke kaila plasma i hoʻonui ʻia i ka nui o ka ʻaole.

Ma hope o ka lawelawe waha, Torvacard, nā papa coated he 95% - 99% bioavailability e hoʻohālikelike ʻia i ka waha o ka waha. He haʻahaʻa loa ka bioavailability o ka atorvastatin (ma kahi o 14%), a me ka loaʻa o ka ʻōnaehana o ka hana pale ma ke ʻano o ka HMG-CoA reductase ma kahi o 30%. ʻO ka bioavailability systemic haʻahaʻa ma muli o ka presystemic metabolism ma ka membous mucous o ka gastrointestinal tract a me / ai ʻole i ka "hele mua" ma o ka puʻu. Hōʻemi ka meaʻai i ka helu a me ka pae o ka inu ʻana i ka lāʻau (e 25% a me 9%, kēlā, e like me ka mea i ʻike ʻia e nā hopena o ka hopena o Cmax a me AUC), akā ke emi nei ka haʻahaʻa lipoprotein haʻahaʻa (LDL-C) e kokoke ana i ka poʻe e lawe ana i ka atorvastatin ma kahi ʻōpū ʻole. Ma hope o ka lawe ʻana i ka atorvastatin i ke ahiahi, ua hoʻohaʻahaʻa ʻia kona kukuna (Cmax a me AUC ma kahi o 30%) ma hope o ka lawe ʻana i kakahiaka. Aia kahi pilina laina ma waena o ke kiʻekiʻe o ka ea a me ka nui o ka lāʻau lapaʻau.

ʻO ka awelika o ka hoʻoili ʻana o ka atorvastatin ma kahi o 381 lita. ʻO ka pilina o ka atorvastatin me nā protein plasma aia ma kahi o 98%. Hāpai

Hoʻomili ʻia ka atorvastatin e ka cytochrome P450 3A4 i nā derivatives o ka ortho- a me para-hy-hydroxylated a me nā ʻano huahana like ʻole o ka beta oxidation. Ivitro ortho- a me para-hydroxylated metabolites he hopena inhibitory ma HMG-CoA reductase, i hoʻohālikelike ʻia me Torvacard. Ma kahi o 70% mau emi i ka hana o HMG-CoA reductase e hele ana ma muli o ka hana o nā metabolites kaila.

Hoʻopau nui ʻia ʻo Atorvastatin i loko o ka bile ma hope o ka hepatic a me / a me ka hoʻokūkū extrahepatic metabolism wale nō. Eia naʻe, ʻaʻole i kau ʻia ka lāʻau lapaʻau i ka recirculation enterohepatic koʻikoʻi. ʻO ka hapalua plasma waena-ola o ka atorvastatin i loko o nā kānaka ma kahi o 14 mau hola. ʻO ka hapalua ola o ka hana pale me ka mālama ʻana iā HMG-CoA reductase ma kahi o 20-30 mau hola ma muli o ka hana o nā metabolite hoʻoikaika. Ma hope o ka lawelawe waha, hōʻemi ma mua o 2% o atorvastatin e loaʻa i ka urine.

ʻO ka Pharmacokinetics i nā hui hoʻomanawanui kūikawā

ʻO nā maʻi maʻi

Ua ʻoi aku ka kiʻekiʻe o ka atorvastatin a me kāna mau neʻe i ka plasma i ke olakino olakino ma mua o 65 mau makahiki a ʻoi aku paha (Cmax ma kahi o 40%, AUC ma kahi o 30%) ma mua o nā maʻi ʻōpio, aʻo ka hopena lipid-hoʻohaʻahaʻa i ka therapy ua hoʻohālikelike ʻia i ka mea i ʻike ʻia ma ka heluna kanaka nā maʻi ʻōpio.

I nā haʻawina loiloi, ʻike ʻia ka kūkaʻi o ka atorvastatin i nā mea maʻi pediatric i like me ia i nā poʻe pākē me ka allometric scaling e ke kaumaha o ke kino. Kahi i ka kiko holoʻokoʻa o ka hoʻohana atorvastatin a me o-hydroxyatorvastatin, he kaohi mau ʻana ma ka haʻahaʻa lipoprotein cholesterol haʻahaʻa (LDL-C) a me ka nui o nā kolamu (XC) i nānā.

Hoʻololi ʻia ka ʻike o ka atorvastatin a me kāna mau neʻe i ka wahine (Cmax ma kahi o 20% kiʻekiʻe a ʻo AUC ma kahi o 10% haʻahaʻa) mai kēlā mau kāne, akā, ʻaʻole i ʻike ʻia ka ʻokoʻa o ka hopena i ka hopena o ka lāʻau ma ka lipid metabolism i nā kāne a me nā wahine.

ʻAʻole pili ka maʻi o ka pūpū i ka hoʻomohala ʻana i ka atorvastatin a me nā metabolites hoʻoikaika i ka plasma koko a me ko lākou hopena lipid-hoʻohaʻahaʻa, no laila, ʻaʻole i koi ʻia ka hoʻoponopono ʻia o nā maʻi like ʻole.

ʻAʻole ia e hoʻomaka i ka hemodialysis e alakaʻi i ka nui o ka hoʻomaʻemaʻe ʻana o ka atorvastatin, ʻo ka mea pili nui ka lāʻau lapaʻau me nā protein plasma.

Hoʻohui ka nui o ka plasma i ka atorvastatin a me kāna mau neʻe i ka nui (Cmax ma kahi o 16 mau manawa, AUC ma kahi o 11 mau manawa) i nā mea maʻi me cirrhosis ate alkohol (keiki-Pugh papa B).

ʻO ka hopena o ka gen polymorphism SLCO1B1

ʻO ka Metabolism ma loko o nā mea āpau o ka HMG-CoA reductase inhibitors, me ka atorvastatin, ka komo ʻana o nā ʻōmole transporter OATP1B1. ʻO nā mea maʻi me ka SLCO1B1 gene polymorphism e hoʻolaha ʻia i ka nui o ka hoʻolaha ʻana i ka atorvastatin, hiki iā lākou ke piʻi nui aʻe o ka rhabdomyolysis. ʻO ka polymorphism ma ka hoʻopili ʻana o ka OATP1B1 (SLCO1B1 c.521CC) i kumu no ka 2.4-paiki i ka piʻi ʻana o ka atorvastatin (AUC) i hoʻohālikelike ʻia i nā poʻe ʻaʻole i loaʻa kēia ʻano o ka genotype (c.521TT). I kēlā mau maʻi, hiki i ka hala ke hōʻeuʻeu o ka hepatic i ka atorvastatin ma muli o kahi maʻi kulia. ʻAʻole maopopo i nā hopena hiki ke loaʻa i kēia hanana i ka maikaʻi o ka lāʻau lapaʻau.

Lapaʻau lāʻau

ʻO Torvacard kahi mea mālama hōʻaiʻē koho i ka hoʻoneʻe ʻia o HMG-CoA, kahi kīme nui e hoʻohuli ana i ka 3-hydroxy-3-methylglutaryl-CoA i ka mevalonic acid, kahi mea i mua i ka steroid, e komo pū kekahi me ka cholesterol.

Hoʻokomo ʻia ka triglycerides Hepatic a me ka cholesterol i nā lipoproteins density haʻahaʻa loa (VLDL), e komo i ke koko koko a lawe ʻia i nā kōpili peripheral. Kūkulu ʻia nā lipoproteins haʻahaʻa (LDL) mai VLDL, kahi i hoʻohālikelike ʻia e ka hoʻopili ʻana me nā receptors me ka pilina kiʻekiʻe no LDL.

ʻO ka Torvacard e hōʻemi ana i ka plasma cholesterol a me nā lipoproteins serum ma o ka lawe ʻana i ka hoʻōla a HMG-CoA a me ka hoʻomakeke hou aku o ka kolosolo o ka kolamu ma ka puʻuwai, a me ka hoʻonui ʻana i ka nui o nā mea hoʻokipa LDL hepatic ma ka papakū, e hoʻomaikaʻi ana i ka hoʻōla a me ka catabolism o LDL-C.

Ua hōʻemi o Torvacard i ka hoʻoneʻe ʻana a me ka helu o nā palapuna LDL. Hoʻokumu ʻo Torvacard i ka hoʻonui nui ʻana a hoʻomau mau i ka hana o nā mea LDL e hui pū me nā loli kūpono i ke ʻano o nā alapuni LDL kuapo. Ua hōʻemi pono ʻo Torvacard i ka pae o ka LDL-C i nā mea maʻi me ka hypercholesterolemia homozygous me ka 20%, kū i ka maʻi me nā lipid-hoʻemi haʻahaʻa.

ʻO ka Torvacard e hōʻemi ana i ka nui o ka kolikoli kolamu ma ka 30-46%, ka LDL cholesterol ma ka 41-61%, ka apolipoprotein B ma ka 34-50%, triglycerides e ka 14-33% a me VLDL i nā mea maʻi me ka heterozygous a me ka homozygous hypercholesterolemia, nā ʻano like ʻole o ka hypercholesterolemia, , aia hoʻi i nā mea maʻi me ka diabetes-mellitus non-insulin-hilinaʻi nui.

ʻO ka hōʻemi i ka kolamu holoʻokoʻa, LDL cholesterol a me apolipoprotein B e hōʻemi i ka hopena o ka hoʻomohalaʻana i ka maʻi cardiovascular a me ka hopena o ka make.

Nā hōʻailona no ka hoʻohana ʻana

- i hui pū me ka papaʻai no ka mālamaʻana i nā poʻe maʻi me ka hoʻonui ʻia o ka plasma nui o ka kolamu a pau o ka kolamu, LDL-C, apolipoprotein B a me ka triglycerides a me ka hoʻonui ʻana o ka HDL-C i nā mea maʻi me ka hypercholesterolemia haʻahaʻa (heterozygous familial a me nā nonopilial hypercholesterolemia), i hui pū ʻia (mix) hyperlipidemia E like me IIa a me IIb e like me Frederickson), me ka nui o ka ʻike o ka triglycerides i loko o ke koko koko (type IV e like me Frederickson) a me nā mea maʻi me dysbetalipoproteinemia (type III like Frederickson), i ka lilo ʻole o kahi hopena kūpono me ka di oterapii

- e hōʻemi i ka nui o ke koko plasma o ka nui o ka kolamu a me LDL-C i nā mea maʻi me ka hypercholesterolemia homozygous me ka hemahema ʻole o ka hoʻohana ʻana i ka papaʻai meaʻai a me nā ʻano lāʻau lapaʻau ʻole non-pharmacological o ka maʻi.

-a hoemi i ka hopena o nā hopena lethal o ka maʻi ʻōpū coronary a me nā hōʻeha o ka hoʻomohala ʻana i ka myocardial infarction, angina pectoris, stroke a me ka hōʻemi ʻana i ka pono no ka revascularization kaʻina i loko o nā maʻi me nā maʻi cardiovascular a / a i ʻole dyslipidemia, me ka ʻike ʻole ʻia kēia mau maʻi. nā hopena pilikia no ka hoʻomohala ʻana i ka maʻi naʻau coronary, e like me nā makahiki he ʻoi aku ma mua o 55 mau makahiki, ka ulaula, ka hypertension arterial, haʻahaʻa ʻana i ka plasma haʻahaʻa o HDL-C, a me nā hihia kūpono o ka hoʻomohala ʻana o ka maʻi naʻau coronary i nā hoahānau

- i hui pū me ka papaʻai no ka mālama ʻana i nā keiki i nā makahiki he 10-17 mau makahiki me ka hoʻonui ʻia o ka plasma momona o ka kolamu ka nui, LDL-C a me ka apolipoprotein B me ka hypercholesterolemia familial heterozygous, inā ma hope o ka lawa ʻana o ka mālamaʻaiʻai ʻai nui i ke pae ʻana o LDL-C e noho mau loa> 190 mg / dl a i ka pae o ka. ʻO ka LDL ka mea> 160 mg / dl, akā aia nā mea i ka hoʻomaka mua ʻana o ka maʻi cardiovascular ma nā ʻohana a i ʻole nā ​​ʻelua a i ʻole nā ​​mea koʻikoʻi no ka hoʻoulu ʻana i ka maʻi cardiovascular ma kahi keiki.

ʻLoe a me ke kākele

Ma mua o ka hoʻohana ʻana iā Torvacard, pono e hoʻokaʻawale ʻia ka mea maʻi i kaʻai lipid-hoʻemi haʻahaʻa, hoʻokolohua a me ka hoʻohaʻemi kaumaha no ka mālama ʻana i ka hypercholesterolemia, me ka mālama ʻana i ka maʻi ma lalo. Pono e mālama ʻia ka papa ʻaina i ka manawa holoʻokoʻa o ka hopena me Torvacard. Koho ʻia ka ʻōkene i kēlā me kēia kanaka ma muli o ka pae mua o ka HDL-C, ka pahuhopu o ka lāʻau a me ka pane ʻana o ka mea maʻi.

ʻO ka maʻa hoʻomaka hoʻomaka he 10 mg hoʻokahi i kēlā me kēia lā. Pono e hoʻoponopono ʻia nā pila ma nā wā he 4 o nā pule paha. ʻO ka dosis kiʻekiʻe loa he 80 mg hoʻokahi i ka lā.

Lawe ʻia ka wai maʻi Torvacard i kēlā me kēia lā i kēlā me kēia manawa o ka lā me ka meaʻai a i ʻole he manawa ʻole o ka manawa. Hoʻoholo ʻia ka lōʻihi o ka mālama ʻana e ke kauka hele mai.

ʻO ka hypercholesterolemia muaa ua huiia(huiia)pālahalaha maʻi

Torvacard 10 mg hoʻokahi i kēlā me kēia lā. Hoʻomaʻamaʻa pinepine ʻia ka hopena therapeutic i loko o 2 mau pule, a ʻo ka hopena therapeutic ākea e hana pinepine ʻia i loko o 4 mau pule. Kākoʻo ʻia ka hopena e ka hoʻomau mau ʻana o ka lāʻau.

Heterozygous familial hypercholesterolemia

Pono ka poʻe maʻi e hoʻomaka i ka mālama ʻana me kahi maʻi o 10 mg i kēlā me kēia lā o Torvacard. Ke koho ʻana i kahi maʻa, pono e hoʻohana ʻia kahi ala ponoʻī, e hoʻoponopono hou ʻia ka lāʻau i kēlā me kēia 4 hebedoma a 40 mg i kēlā me kēia lā. Ma hope o kēia, hiki ke hoʻonui ʻia i ka hopena o Torvacard i ka nui o 80 mg i hoʻokahi lā a i ka 40 mg hoʻokahi i ka lā i hiki ke lawe ʻia i loko o ka lā me ka lāʻau e hoʻonui ai i ka ʻāʻī o ka bile acid.

Homozygous familial hypercholesterolemia

ʻO ka makeʻana o Torvacard i nā mea maʻi me ka hypercholesterolemia homozygous homozygous mai 10 a 80 mg i kēlā me kēia lā. Pono e hoʻohana ʻia ʻo Torvacard i kēia mau maʻi e like me ka hoʻohui i nā ʻano lāʻau ʻē aʻe o ka lipid-lowering therapy (no ka laʻana, ʻo LDL apheresis), a i ʻole loaʻa ʻole ia ʻano maʻi.

Nā kikowaena Cardio-maʻi vascular

Me ka pale mua, ka maʻa lāʻau he 10 mg / lā. Hiki iā ia ke koi i nā dosis kiʻekiʻe (ʻoi aku ma mua o 10 mg i kēlā me kēia lā) e hoʻokō i kāu pae kolamu kiʻekiʻe (LDL), e like me ke kauka ʻana e kāu kauka.

ʻAʻole pono ke hoʻoponopono ʻia.

Pono e hoʻohana ʻia ʻo Torvacard me ka akahele me ka poʻe maʻi me ka maʻi hepatic. Loaʻa Torvakard contraindicated i nā maʻi me nā maʻi maʻa ikaika.

ʻO nā maʻi maʻi

Wahi a nā hualoaʻa o nā haʻawina o ka pono a me ka palekana o ka lāʻau lapaʻau, ʻike ʻia nā mea maʻi ma mua o 70 mau makahiki e hoʻohana i nā dosis like i nā mea i hoʻohana ʻia no nā maʻi āpau o nā maʻi.

Hoʻohana ʻo Pediatric

Pono ka hoʻohana ʻana i ka maʻi pediatrics e nā kauka wale nō me ka ʻike ma ka mālama ʻana i ka hyperlipidemia pediatric, ʻoiai e ʻike pono ʻia nā mea maʻi e nānā i ka holomua i hana ʻia.

No nā mea maʻi 10 mau makahiki a ʻoi aku ka ʻoi aʻe, ʻo ka ʻōlelo hoʻomaka ʻana o ka atorvastatin he 10 mg i kēlā me kēia lā me ka titration a hiki i 20 mg i kēlā me kēia lā. Pono e hoʻokomo i ka Titration ma muli o kahi ʻano kū hoʻokahi a noʻonoʻo i ka hoʻomanawanui o ka lāʻau lapaʻau i nā mea maʻi pediatric. I kēia manawa, ʻōlelo liʻiliʻi ka mea e pili ana i ka palekana o ka lāʻau lapaʻau no nā keiki i loaʻa nā pona ma luna o 20 mg, kahi e like me ka nui o 400 mg / kg.

Aia ka ʻike palena ma ka mālama ʻana i nā keiki me ka lāʻau lapaʻau 6 ka 10 mau makahiki. ʻAʻole i kuhikuhi ʻia ʻo Atorvastatin no ka mālama ʻana i nā keiki ma lalo o 10 mau makahiki.

ʻO nā palapala ʻē aʻe / ʻano paʻa ʻē aʻe i kūpono no kēia pae o nā maʻi.

Kuhi ʻia ʻo Torvacard no ka hoʻokō waha. Lawe ʻia kēlā me kēia lā o Torvacard i hoʻokahi manawa holoʻokoʻa i kēlā me kēia manawa o ka lā, me ke ʻano o ka ʻai ʻana o ka meaʻai.

Nā hopena hopena

Ka mea i loaʻa i nā hopena maikaʻi loa i nā hoʻokolohua hoʻokolohua i hoʻopaʻa ʻia ma lalo nei me ka hoʻohana ʻana i kēia mau ʻano i ʻike ʻia: pinepine (≥1 / 100 a hiki i 1/10), ʻaʻole pinepine (≥ 1/1000 a 1/100), hemahema (≥ 1/10000 a 1 / 1000), aneʻi loa (a hiki i ka 1/10000), me ka ʻike ʻole (ʻaʻole hiki ke koho ʻia mai ka ʻike ʻike).

- ʻeha ma ka pharynx a me ka larynx, nosebleeds

- constipation, flatulence, dyspepsia, nausea, ʻeha

- myalgia, arthralgia, ʻeha i loko o nā ʻōpū, nā ʻōpū o ka hoʻoheʻe, ka ʻōpū o nā ʻanā, ka ʻeha hoʻi

- ka haʻaleleʻana o nā ʻāpana ʻana o nā hana ʻalika i nā hana ate, kahi hoʻonui i ka pae o ka kinase kinase i ke koko

- hypoglycemia, kaupaona momona, anorexia

- nā pō poʻokela, hina

- dizziness, paresthesia, hyposthesia, dysgeusia (ʻokoʻa kūʻono), amnesia

- ka luaʻi, ʻeha ma nā ʻaoʻao o luna a me lalo o ka ʻōpū o ka ʻōpū, ka belching, ka pancreatitis

- urticaria, ʻehaʻeha, ʻeha, alopecia (focal alopecia)

- ʻeha ka ʻāʻī, ke ʻokiʻī o ka naʻau

- malaise, nāwaliwali laulā, nā ʻeha ʻeha, nā edema peripheral, kaʻilihune, hyperthermia

- ke komoʻana o nā keʻena koko keʻokeʻo i ka urine

- ʻO ka edema o Quincke, dermatitis bullous, me ka erythema polymorphic, Steven-Johnson syndrome a me nā meaʻino o ka epidermal necrolysis

- myopathy, myositis, rhabdomyolysis, tendinopathy (hōʻeha tendon), i kekahi manawa i paʻakikī e ka hakahaka

ʻIke pinepine ʻole(hiki ʻole ke hoʻoholo mai ka ʻikepili i loaʻa)

- myopathy hoʻomalu-immuno

Me kekahi mau statins

- kūpeʻe o ka hana moekolohe

- nā hihia ʻokoʻa o ka maʻi ʻeha interstitial, ʻoi aku me ka hoʻomehana lōʻihi

- Diabolo mellitus: pili ka alapine i ka hele a ʻaʻole ʻole i nā mea pōʻino (ʻo ka wikiwiki o ka hoʻoliʻi ʻana o ke koko glucose ma mua o 5.6 mmol / L, BMI ʻoi aku ma mua o 30 kg / m2, triglycerides kiʻekiʻe, mōʻaukala o ka hypertension).

E like me nā HMG-CoA reductase inhibitors, nā mea maʻi e loaʻa ana i atorvastatin i loaʻa i ka hoʻonui i nā transaminases. ʻO kēia mau loli, e like me ke kānāwai, nāwaliwali, pōkole ka manawa ʻaʻole ia e koi ʻia ka hopena o ka mālama ʻana. ʻO kahi hoʻonui hoʻonui maʻi maʻi (ʻoi aku ka 3 mau manawa ʻoi aʻe ma mua o ka palena o ka maʻamau) o nā transaminases serum i loaʻa i ka 0.8% o nā maʻi e lawe ana i ka atorvastatin. ʻO kēia hoʻonui i hilinaʻi-dosis a hoʻihoʻi i nā maʻi āpau.

ʻOi aku ka nui o 3-melu ka nui o ka palena o ka maʻamau no ka pae serum creatine kinase (CC) i nānā ma ka 2,5% o nā mea maʻi e lawe ana i atorvastatin, kahi hōʻailona like i ʻike ʻia i ka wā o nā hoʻokolohua lapaʻau a no nā poʻe HMG-CoA reductase inhibitors. ʻO 10 ka nui o ka nui o ka palena o luna o ka maʻamau i hele i 0.4% o nā mea maʻi e lawe ana i atorvastatin.

ʻAoʻaonā hana i nā keiki

- hoʻonui i ke kiʻekiʻe o ALT, hoʻonui nui i nā kiʻekiʻe o ka phosphokinase i loko o ke koko

Wahi a nā ʻike i loaʻa, hiki ke manaʻo i ka leʻa maʻamau, ʻano a me ka nui o nā ʻino maikaʻi loa i nā keiki e lawe ana i ka atorvastatin e like nō me ka pākeke. I kēia manawa, palena mau ʻikepili e pili ana i ka palekana lōʻihi o ka lāʻau no nā maʻi maʻi pediatric.

Nā Hoʻohui

- hypersensitivity o kekahi o nā lāʻau o ka lāʻau

- maʻi maʻi patia a i ʻole ka hoʻonui ʻana i ka hana o ka seramin transaminases (ʻoi aku ma mua o 3 mau manawa e hoʻohālikelike ʻia me ka palena palena o ke kumu) o ka kumu ʻike ʻole.

- nā mea maʻi me ka lactose intolerance hoʻoilina, hemahema o ka enzyme LAPP-lactase, malabsorption o glucose-galactose

- ka wahine a me ka lactation, a me nā wahine o ka wā o ka hānau ʻana i hoʻohana ʻole i nā ala kūpono o ka contraception

- nā keiki ma lalo o 10 mau makahiki

Hoʻopili i nā lāʻau lapaʻau

ʻO ka hopena o nā lāʻau lapaʻau paʻa i ka hopena o ka atorvastatin

Hoʻopili ʻia ka Atorvastatin e ka cytochrome P4503A4 (CYP3A4) a he kekuhi o ka protein o ka halihali, no ka laʻana, hepatic uptake transporter - OATP1B1. ʻO ka hoʻohana like ʻana o nā lāʻau lapaʻau e pale i ka CYP3A4 a i ʻole ka lawe i ka protein e alakaʻi i ka nui o ka neʻe o ka atorvastatin i loko o ke kō koko a hoʻonui i ka pilikia o ka myopathy.

Eia kekahi, piʻi ka hopena i ka wā e lawe ana i ka atorvastatin me nā lāʻau ʻē aʻe e hiki ai i ke myopathy, no ka laʻana, me nā derivatives o ka fibric acid a me ka ezetimibe.

Ua hōʻike ʻia nā inhibitor CYP3A4 ikaika e hoʻonui nui i nā kukuna atorvastatin. ʻO ka hoʻohana like ʻana o nā mākeke CYP3A4 ikaika (no ka laʻana, ka cyclosporine, telithromycin, clarithromycin, delavirdine, styripentol, ketoconazole, voriconazole, itraconazole, posaconazole a me HIV protease inhibitors, me ka ritonavir, lopinavir, atazanav, lacinavir, atazanav, . ^ E Ha yM. Inā ʻaʻole e hoʻokaʻawale ʻia ka lawelawe ʻana o kēia mau lāʻau me ka atorvastatin, pono e hoʻemi ʻia ka pehu mua a me ka nui o ka atorvastatin, a e pono ai ke mālama ʻia ʻana o nā maʻi maʻi.

Nā CYP3A4 Hoʻolaha Moderine

Hiki i nā mea hoʻohālikelike CYP3A4 inhibitors (e.g., erythromycin, diltiazem, verapamil a me fluconazole) hiki ke hoʻonui i ka hoʻololi ʻana o ka plasma o atorvastatin. Hoʻopili ʻia ka mahuahua nui o ka myopathy i ka wā e hoʻohana ai ka erythromycin i hui pū me nā statins. ʻAʻole i hana ʻia nā noi ʻana o ka hoʻohālikelike ʻana i nā lāʻau me ka hoʻopaʻa ʻana i nā hopena o ka amiodarone a i ʻole verapamil ma ka atorvastatin. Ua hoʻokūpaʻa ua hiki mai i ka amiodarone a me verapamil i ka hana o CYP3A4, no laila, ko lākou hui pū ʻia me ka atorvastatin hiki ke alakaʻi i ka hoʻonui i kāna hana. No laila, he mea pono e kuhikuhi i kahi lāʻau haʻahaʻa o ka atorvastatin a ke manaʻo ʻia nei e alakaʻi i ka nānā ʻana i nā lapaʻau kūpono kūpono o nā mea maʻi a ʻo ke lawe ʻana i ka lāʻau lapaʻau me nā CYP3A4 inhibitors hana. Hōʻike ʻia nā ʻike loiloi kūpono ma hope o ka hoʻomaka ʻana o ka ʻoihana a i ʻole ka pau ʻana o ka hoʻoponopono ʻana o ka mea paʻa.

ʻO ka hoʻohana ʻana i ka atorvastatin me ka inducers cytochrome P4503A (no ka laʻana, me ka efavirenz, rifampicin, wort a St. John) hiki ke alakaʻi i kahi hoʻololi i ka hoʻoliʻiliʻi o ka atorvastatin i ka plasma. Ma muli o ka hana pālua o ka hui o ka rifampicin (ka wai o ka cytochrome P4503A a me ka pale ʻana o ka transporter o ka hoʻihoʻi ʻana o ka lāʻau ma ka ʻĀina OATP1B1), ka hoʻohana pinepine ʻana o ka atorvastatin a me nā rifampicin, no ka mea, ʻo ka lawe ʻana i ka atorvastatin i kekahi manawa ma hope o ka rifampicin e hoʻolilo i ka emi nui o ka pehu o ka atorvastatin. Eia nō naʻe, ʻaʻole i hoʻokū ʻia ka hopena o ka atorvastatin ma ke ʻano o ka rifampicin i nā hepatocytes, no laila, inā ʻaʻole i hiki ke hoʻohana pono ʻia ka hoʻohana ʻana me ka mālama pono ʻana o ka poʻe maʻi me ka manaʻo e hana i ka hopena o ka hopena.

Nā mea hoʻonani protote

ʻO ka lawe ʻana i nā mea pale o ka lawena (e.g., cyclosporine) e hoʻomaikaʻi i ka hopena holoʻokoʻa o ka atorvastatin. ʻAʻole ʻike ka hopena o ka pale ʻana i ka lawe ʻole ʻana o nā mea lawe aku i ka lāʻau lapaʻau ma o ka ʻili ma ka paʻa ʻana o ka atorvastatin i nā hepatocytes. Inā hiki ʻole ke hoʻohana concomitant, hiki ke hōʻemi i ka nui o ka hopena a mālama i ke nānā ʻana i nā maʻi o ka hopena o ka hopena.

ʻO nā mea hoʻoili maikaʻi o Gemfibrozil / fibroic

ʻO ka Fibrate monotherapy i kekahi manawa e hoʻoulu i nā pilikia ma ka ʻōnaehana muscular, me ka rhabdomyolysis. Hiki i kēia ke kūleʻa me ka hoʻohana ʻana o ka hoʻohana fibroic acid a me atorvastatin. Inā hiki ʻole ke hoʻohana concomitant, i mea e hoʻokō ai i kahi pahuhopu therapeutic, pono ia e kuhikuhi i nā poki liʻiliʻi loa o ka atorvastatin a me ka mālama pono ʻana i nā mea maʻi.

Hoʻokomo ʻo Ezetimibe monotherapy i nā pilikia ma ka ʻōnaehana muscular, me ka rhabdomyolysis. No laila, hoʻonui ʻia kēia pilikia me ka hoʻohana me ka ezetimibe a me ka atorvastatin. Kūkaha ʻia nā māka kūpono e pili ana i nā mea maʻi.

Hōʻike ʻia ka ʻike o ka atorvastatin a me kāna mau neʻe i nā kaila plasma (ma kahi o 25%) i hoʻohālikelike ʻia me ka concomitant therapy me colestipol a me atorvastatin. ʻO ka hopena ma ka pae o nā lipids ua ʻoi aku ka nui me ka hoʻokahuli like ʻana o ka atorvastatin a me ka hoʻomākaukau ʻana colestipol i hoʻohālikelike ʻia me ka pae o ka monotherapy me kēia mau lāʻau.

ʻAʻole i hana ʻia nā haʻawina no ka pilina o ka atorvastatin a me ka waikawa fusidic. E like me nā statins ʻē aʻe, i ka wā o ka nānā ʻana i ke kākau inoa ʻana o ka hoʻokūkū concomitant me ka atorvastatin a me ka waikawa fusidic, ua ʻike ʻia nā pilikia o ka iwi, me ka rhabdomyolysis. ʻAʻole maopopo ka ʻike o kēia kaʻikepili. Pono ka nānā kiaʻi pono ʻia o nā mea maʻi, a i kekahi mau mea, ke kāpae nei i ka pōkole i ka hoʻokele o ka atorvastatin.

ʻOiai ʻaʻole i mālama ʻia nā haʻawina pili o ka atorvastatin a me ka colchicine, ua hōʻike ʻia nā hihia o ka myopathy me ka terapi concomitant me ka atorvastatin a me ka colchicine, a no laila e pono e mālama ʻia ka mālama ʻana i ka wā e kuhikuhi ai i ka atorvastatin me ka colchicine.

ʻO ka hopena o ka atorvastatin ma nā lāʻau like

Me ka hoʻohana pū ʻana o nā koina o ka digoxin a me 10 mg o ka atorvastatin, ua hoʻonui iki ʻia ka nui o ka kūmole kaulike. ʻO nā maʻi maʻi e lawe ana i ka digoxin e kau ʻia ma ke kāohi ma ke ʻano maʻi.

ʻO ka hui pū ʻana o ka atorvastatin a me ka maʻi kūlohelohe waha e hoʻolōʻihi i ka komo ʻana o ka plasma o ka norethindrone a me ka ethinyl estradiol.

ʻAʻole i ʻike pū ʻia kekahi hopena olakino koʻikoʻi o ka atorvastatin me warfarin.

Hoʻi ʻia loa nā hihia nā hana pilikino pili maʻi me nā anticoagulants. Ma mua o ka hoʻomaka ʻana i ka mālama ʻana me ka atorvastatin a ma ka hoʻomaka ʻana o ka mālama ʻana, e koho ʻia e hoʻoholo i ka manawa o ka prothrombin i nā mea maʻi e lawe ana i nā anticoagulants coumarin.

Noi ʻia e hoʻohaʻahaʻa i ka palena mua a e mālama i ka mālama ʻana i nā maʻi ma nā maʻi e lawe ana i ka atorvastatin a me ke boceprevir i ka manawa like. ʻAʻole pono ʻo ka mahele o kēlā me kēia lā o ka atorvastatin ma mua o 20 mg i ka manawa concomitant therapy me boceprevir.

Ua mālama ʻia nā noi ʻana i ka lāʻau lapaʻau me nā pākeke. ʻAʻole maopopo ka loaʻa o ke ʻano o ka lāʻau lapaʻau i nā keiki. Hōʻike ʻia nā hōʻailona o ke kamaʻilio ʻana no nā pākeke ma luna, no laila, i ka wā e mālama ai i nā keiki, "pono ​​e noʻonoʻo ʻia nā ʻōlelo aʻoaʻo".

Ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu ʻana

Hoʻohana ʻia ka lāʻau lapaʻau ma ke kumu o nā papa o ke keʻokeʻo a i ʻole kokoke loa hoʻi i ke keʻokeʻo keʻokeʻo, ka mea i pani ʻia me ka membrane kiʻi, ʻo ia ka biconvex a me ka oval.

• 1 papa i loaʻa iā 40, 20 mg a i ʻole 10 mg o ka atorvastatin.

Nā lāʻau lapaʻau a me nā lāʻau lapaʻau: lipid-hoʻemi haʻahaʻa.

Nā ʻōlelo kikoʻī

Ka hana i luna

Ma mua o ka hoʻomaʻamaʻa ʻana a me kēlā me kēia manawa ma hope o ka pau ʻana, pono e hana ʻia nā haʻawina o ka hana ate. Eia kekahi, pono e hoʻomaʻamaʻa i nā hana koʻikoʻi i nā maʻi i nā mea maʻi me nā hōʻailona a i ʻole kahi hōʻailona e hōʻike ai i ka hōʻino o ka ate. I ka hihia o ka hoʻonui o ka ʻike i nā transaminases hepatic, pono e nānā ʻia kā lākou pae a hiki i ka palena o ke ʻano maʻamau. Ināʻoi aku ka piʻi o nā pae transaminase ma mua o 3 mau manawa o ka palena o ka maʻamau, hoʻomau ka mea, e pono ai e hoʻemi i ka ʻōpū a hoʻopau paha i ka maʻi.

Pono e hoʻohana ʻia ʻo Torvacard me ka mālama ʻana i nā maʻi i hoʻopau i ka nui o nā mea inu ʻawaʻawa a me / a i ʻole he mōʻaukala o ka maʻi ate.

ʻO nā mea maʻi i loaʻa i ka hōʻeha hemorrhagic a i ka nee ischemic attack wale nō.

No nā mea maʻi i loaʻa i ka ʻeha hemorrhagic a i ʻole ka lacunar infarction o ka lolo, ʻaʻole maopopo ka paleʻana o nā hōʻemi a me nā pono o 80 mg o atorvastatin. I kēlā mau mea maʻi, ma mua o ka hoʻomaka ʻana i ka mālama ʻana, pono e noʻonoʻo pono ʻia ka hopena o ka ʻeha o ka hemorrhagic.

He hana huapili o nā iwi

ʻO Torvacard, e like me nā mea ʻē aʻe o ka HMG-CoA reductase, hiki i nā hihia ʻona ke hoʻopili i nā ʻāeʻe a me nā kumu myalgia, myositis, myopathy, kahi e hiki ai i ka holomua i ka rhabdomyolysis, kahi maʻi hoʻoweliweli ola e hōʻike ʻia e ka nui nui o nā kiʻekiʻe o ka phosphokinase level (ma 10 mau manawa kiʻekiʻe ma mua o ka palena o ka maʻamau o ka maʻamau (VGN), myoglobinemia a me myoglobinuria, hiki ke alakaʻi i ka hoʻomohala ʻana o ka hana renal.

Pono e hoʻohana ʻia ʻo Torvacard me ka makaʻala i nā mea maʻi me nā mea e predisposing no ka hoʻomohala ʻana o ka rhabdomyolysis. Pono ke ana o ka pae o ka phosphokinase (CPK) ma mua o ka mālama ʻana me nā statins i nā kūlana i lalo:

nā pōʻino hōʻeha hoʻoilina ma kahi mōʻī pilikino a pilikino paha

ka mōʻaukala hoʻonaninani o ka ʻiʻo ma muli o ka statin a i ʻole ka mōʻaukala nāu

ka mōʻaukala o ka maʻi pāpaʻi a me / a i ʻole ka inu ʻawaʻawa nui

- i nā mea maʻi ʻelemakule (ma mua o 70 mau makahiki), pono ke noʻonoʻo ʻia ka pono o kēia mau ana e noʻonoʻo ai i ka loaʻa ʻana o nā mea e ʻike ai no ka hoʻomohala ʻana o ka rhabdomyolysis.

- nā kūlana i hiki ke piʻi aʻe ma ka pae o kekahi mau mea o ka plasma koko, me ka laʻa, me ka ʻike pū ʻana o nā lāʻau lapaʻau, a me nā ʻāpana kūikawā o nā maʻi, me ka poʻe me nā maʻi hoʻoilina.

I kēlā mau kūlana, pono e noʻonoʻo ʻia ka pilikia o ka mālama e pili ana i nā pōmaikaʻi ʻokoʻa, a ua ʻōlelo ʻia ka nānā ʻana o ka maʻi lapaʻau. ʻAʻole hoʻomaka nā Therapy inā ʻoi aku ka kiʻekiʻe o nā pae o ka CPK (ʻoi aku ma mua o 5 mau manawa iʻoi aku ma mua o VGN).

Hana ʻia Kinase Papa Mokuna

ʻAʻole ʻoe e ana i ka pae o ka hōʻola phosphokinase (CPK) ma hope o ka hana kino kino a i ʻole ke alo ʻia paha o kahi kumu e hiki ai i ke kumu no ka hoʻonui ʻana o ka CPK, no ka mea kēia e hoʻopiʻi i ka hoʻākāka o nā waiwai. Inā nui ka pae o CPK i ka pae mua (ma mua o 5 mau manawa i ʻoi aku ma mua o VGN), e hōʻoia i ka hopena, e hoʻomau i ka noiʻi ma hope o 5 a 7 lā.

ʻO ka ʻike maʻi

Hoʻomaʻamaʻa ʻia nā mea maʻi e pili ana i ka pono e hōʻike koke i ka loaʻa ʻana o ka ʻeha o ka naʻau, ka maʻi a me ka nāwaliwali, keu inā ua hele pū ʻia me ka malaise a i ʻole ke maʻi paha. Inā hele kēia mau ʻōuli i ka wā e mālama ai me Torvacard, a laila pono e ana ke kiʻekiʻe o ka CPK. Inā piʻi nui nā pae CPK i ʻike ʻia (ʻoi aku ma mua o ka 5 mau manawa i ʻoi aku ma mua o ka palena o ka maʻamau), hōʻeha nā hōʻailona ʻeha a hoʻomāinoino ʻia i kēlā me kēia lā, pono ʻoe e noʻonoʻo e hoʻolilo i ka hana maʻi.

Inā hele ʻole nā ​​ʻōuli a hoʻi mai ka pae ma CPK maʻamau, pono e noʻonoʻo e hoʻohana hou iā Torvacard a i ʻole ka hoʻohana 'ana i nā statin liʻuliʻu ma nā liʻiliʻi liʻiliʻi a me ka mālama pono ʻana.

Pono e hōʻoki ʻia ʻo Atorvastatin inā ʻike ʻia ka nui o ka maʻi ma ke kiʻekiʻe o QC (ʻoi aku ka 10 mau manawa kiʻekiʻe ma mua o VGN), a i ʻole e loaʻa ka rhabdomyolysis a i ʻole kānalua o kēia maʻi.

Pili pilika hana? anakekahihoʻōlahoʻāla

Hōʻalo ka hōʻeha o ka rhabdomyolysis me ka hoʻohana ʻana i ka atorvastatin i ka manawa like me kekahi mau lāʻau e hiki ke hoʻonui i ka ʻai o ka atorvastatin i loko o ke koko koko, no ka laʻana, me ka ikaika CYP3A4 inhibitors a i ʻole ka lawe i ka protein (e like me ka cyclosporine, telithromycin, clarithromycin, delavirdine, styripentol, itraconazonazole a me nā inhibitor o ka protease HIV, me ka ritonavir, lopinavir, atazanavir, indinavir, darunavir, saquinavir, fosamprenavir, etc.). Eia kekahi, e hoʻonui nui aʻe nō ka hopena o ka myopathy me ka hoʻohana ʻana i ka gemfibrozil a me nā mea ʻē aʻe o ka fibroic acid, boceprevir, erythromycin, niacin a ezetimibe, telaprevir, a i ʻole hui pū ʻana o ka tipranavir / ritonavir. Ma kahi o kēia mau lāʻau, inā hiki, e noʻonoʻo e hiki i ke koho ʻana i nā lāʻau lapaʻau (me ka pili ʻole e pili ana).

Ua hōʻike pinepine ʻia hoʻi ka hoʻopili ʻana i ka maʻi myopathy paʻa-mediated (IONM) i ka manawa a ma hope o ka mālama statin. Hoʻomaʻamaʻa ʻia ka IONM e ka hoʻomau ʻana o ka hoʻāʻo ʻana o ka hoʻāla palupalu a me ka nui o ka hana serum creatine kinase, e hoʻomau nei, ʻoiai me ka pau ʻana o ka mālama statin.

Inā hui pū ka lawelawe ʻana o kēia mau lāʻau me ka atorvastatin, pono e noʻonoʻo pono nā pono a me nā pilikia o ka concomitant therapy. Inā lawe nā mea maʻi i nā lāʻau e hoʻonui ai i ke kaila o ka plasma o atorvastatin, ke kahakaha ʻia e hoʻokaʻawale ʻia ka nui o ka laikini o ka atorvastatin. Ma ka hoʻohana ʻana o nā mea paʻa CYP3A4 ikaika, pono e kuhikuhi i kahi haʻahaʻa haʻahaʻa haʻahaʻa o ka atorvastatin, a ke ʻōlelo pū ʻia nei hoʻi e hoʻokō pono i ka mālama maʻi lapaʻau o kēia mau maʻi.

ʻAʻole hoʻolako ʻia ka hoʻohana pinepine ʻana o ka atorvastatin a me ka waikawa fusidic, no laila, hiki ke hoʻokaʻawale iki ʻia ka lāʻau atorvastatin i ka wā o ka mālama ʻana me ka waikele fusidic.

Hoʻohana ʻo Pediatric

ʻAʻole paʻa ka palekana o ka lāʻau lapaʻau a me kona hopena i ka hoʻolālā ʻana o nā keiki.

ʻO ka maʻi māmā interstitial

ʻO nā hihia nui i nānā pinepine ʻia o ka maʻi interstitial lung i hōʻike ʻia me ka hoʻohana nui ʻana o kekahi mau statins. ʻO nā hōʻailona aʻe i nānā ʻia: ke pōkole o ka hanu, huaʻai ʻole a me ka hōʻemi ma ke olakino holoʻokoʻa (nā luhi, ke kaumaha, a me ke maʻi.) Inā he kānalua i ka mea maʻi i ka maʻi pulmonary interstitial, pono e hoʻokaʻawale ke ʻano statin.

Hōʻike kekahi mau hōʻike i nā statins ma ke ʻano o nā lāʻau lapaʻau e hoʻonui i ka glucose koko, a ma kekahi o nā mea maʻi i hiki ke piʻi i ka hoʻomohala ʻana i ka maʻi diabetes, hiki i ka hyperglycemia ke hōʻea i kahi e pono ai ke kuhikuhi i kahi ʻano maʻi maʻi maʻamau. Eia naʻe, hoʻonāukiuki ʻia kēia hana hōʻemi e ka hopena o ka ulu ʻana i nā maʻi vascular me ke kōkua o statins a no laila, ʻaʻole pono ia ke kumu no ka pani ʻana i ka mālama ʻana me nā statins. ʻO ka nānā ʻana i nā mea maʻi e hōʻemi ʻia (me ka wikiwiki o ka glucose o 5.6-6.9 mmol / l, BMI> 30 kg / m, na kiʻekiʻe triglycerides, hypertension) pono e lawe ʻia e nā lāʻau kūloko a me nā hopena hoʻomalu biochemical i like me ke ʻano nā ʻōmole lahui.

ʻAʻole hoʻohana ʻia ka hoʻohana ʻana o ka nui o nā wai o ka hua mānē i ka wā e lawe ana i ka atorvastatin.

Loaʻa ka Torvacard i ka monabolat lactose. ʻO nā mea maʻi me nā galactose intolerance maʻamau i loaʻa ʻole, ka hemahema o Lapp lactase a i ʻole malabsorption glucose-galactose.

Hoʻokomo ʻia ka Torvacard i ka wā hāpai. Pono nā wahine o ka hānau keiki ʻana e lawe i nā hana hoʻohālikelike kūpono i ka wā o ka mālama ʻana me Torvacard. ʻAʻole i hoʻokele ʻia e nā haʻawina loiloi ma atorvastatin i nā wahine hāpai. He nui nā hōʻike e pili ana i nā abnormalities congenital ma hope o ka hoʻolaha ʻana i ka intrauterine i ka HMG-CoA reductase inhibitors. Ua hōʻike ʻia nā haʻawina holoholona i ka hopena o ka lāʻau i ka hopena o ka hana hānau.

ʻO ka mālamaʻana o ka makuahine me ka atorvastatin hiki ke hōʻemi i ka hoʻololi ʻana o ka mevalonate i loko o ka pūpū, kahi mea i pae i ka biosynthesis cholesterol. No ka mea, he hopena maʻi ʻo ka atherosclerosis, ʻo ka hoʻopau ʻia o ka mālama lipid-hoʻohaʻahaʻa i ka wā hāpai ʻana he liʻiliʻi iki ka hopena o nā hopena lōʻihi e pili ana i ka hypercholesterolemia primer. No laila, ʻaʻole ʻo Torvacard e lawe ʻia e nā wahine hāpai, nā wahine nāna e hoʻolālā nei i ka hapai a i ʻole kānalua. Pono ke kāpae ʻia ka lāʻau Torvacard i ka wā hāpai, a hiki i kahi paʻa i ka ʻāpopo ʻole ʻole ka wahine.

ʻAʻole ʻike nā ʻikepili e pili ai i ka atorvastatin i ka waiū kanaka. I nā lālani, ʻo ka pane ʻana o ka atorvastatin a me nā mea hoʻonaninani o ka plasma i like like me ko lākou kaū o ka waiū. Ma muli o ka hopena no ka hopena maikaʻi, ʻaʻole pono nā wahine e lawe iā Torvacard i ka hānai umauma. Atorvastatin ua contraindicated i ka wā lactation.

Nā hiʻohiʻona o ka hopena o ka lāʻau lapaʻau ma ka hiki ke lawe i kahi kaʻa a me nā mea kikowaena keu

Hāʻawi i nā hopena kūpono o ka lāʻau lapaʻau, pono e hoʻomaʻamaʻa i ka wā o ke kaʻa ʻana i nā kaʻa a me nā mea hoʻokūkū ʻē aʻe.

Ka hana lāʻau lapaʻau

ʻO ka lāʻau lapaʻau Torvacard, ʻo ia ka mea lilo i mākaʻikaʻi koho koho HMG-CoA reductase, e hele i ka hōʻemi o ke kolamu koko. Maikaʻi ʻo Torvacard e pili ana i ka hope o ka hypercholesterolemia homozygous famo, a i ka nui o nā hihia, ʻaʻole hiki ke mālama ʻia i ka maʻi me nā lāʻau like ʻole.

Hoʻomaopopo ka hopena therapeutic hopena ma hope o 1.5-2 mau pule, a me ka nui - ma hope o hoʻokahi mahina. Eia kekahi, i ka wā e hiki mai ana, ʻo mālama ʻia ka hopena o ka lāʻau lapaʻau.

Nā ʻōkuhi no ka hoʻohana

Pono ka lawe ʻia o Torvacard i kēlā me kēia manawa o ka lā, me kahi mea ʻole o ka ʻai. Ma mua o ke kuhikuhi ʻana i ka lāʻau lapaʻau, ua hōʻike ʻia ka mea maʻi i kahi meaʻai lipid-hoʻemi haʻahaʻa, pono ia e mālama pono ai i ka holoʻokoʻa o ka mālama ʻana.

Koho ʻia ka ʻāʻālua ma kahi hoʻokahi, e noʻonoʻo ana i nā hōʻailona kumu mua o LDL-C, ka pahuhopu o ka mālama ʻana a me ka pane ʻana o ka mea maʻi i ka lāʻau.

• ʻO ka ma mua mau ka awelika o 10 mg 1 mau lā / lā. Hoʻololi nā ʻōhua mai 10 a 80 mg 1 mau lā / lā. Hiki i ka lāʻau lapaʻau ke loaʻa i kēlā me kēia manawa o ka lā, me ke ʻano o ka manawa ʻaina. Koho ʻia ka ʻōkole me ka lawe ʻana i nā pae mua o LDL-C, ke kumu o ka lāʻau a me ka hopena pilikino. I ka hoʻomaka ʻana o ka lāʻau lapaʻau a me / a i ka manawa o ka hoʻonui i ka mahele o Torvacard, pono ia e nānā i nā pae lipid plasma a i nā wiki he 2 ma ka hopena o ka hoʻoponopono ʻana ma muli. ʻO ka dosis kiʻekiʻe loa i kēlā me kēia lā he 80 mg ma 1 pāʻai.
• Me ka hyperlipidemia i hui ʻia a me ka hypercholesterolemia mua, ma ke ʻano he kānāwai, ka pā ʻana o 10 mg hoʻokahi manawa i ka lā i lawa ʻia, kahi hopena koʻikoʻi o ka mālama ʻana ma hope o 2 mau pule. Ma hope o 4 wiki, hōʻike pinepine ʻia ka hopena therapeutic, e hoʻomau nei me ka mālama lōʻihi.

Hoʻomaopopo ka hopena therapeutic i hōʻike ʻia ma hope o 2 mau pule o ka hoʻolālā ʻōnaehana me Torvacard, a me ka nui - ma hope o hoʻokahi mahina. Wahi a nā loiloi o Torvacard mai nā mea maʻi, me ka hoʻohana mau ʻana i ka lāʻau, mālama ʻia ka hopena therapeutic i mālama ʻia.